ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 04. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
SUN JEONGHOON [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-02-04, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 |
|---|
| Patentnummer: |
CA3145885 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000954187 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000954187 | ||
| 003 | DE-627 | ||
| 005 | 20240329160906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000954187 | ||
| 035 | |a (EPA)CA3145885 | ||
| 035 | |a (EPA)72139691 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a SUN JEONGHOON |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANTI-MS4A4A ANTIBODIES AND METHODS OF USE THEREOF |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-02-04, Last update posted on www.tib.eu: 2024-03-25, Last updated: 2024-03-29 | ||
| 520 | |a The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HO WEI-HSIEN |4 aut | |
| 700 | 0 | |a ALHAWAGRI MUHAMMAD A |4 aut | |
| 700 | 0 | |a KONG PHILIP LING |4 aut | |
| 700 | 0 | |a RHINN HERVE |4 aut | |
| 700 | 0 | |a LONG HUA |4 aut | |
| 700 | 0 | |a SRINIVASAN KARPAGAM |4 aut | |
| 700 | 0 | |a MITRA ANANYA |4 aut | |
| 700 | 0 | |a BERMINGHAM DANIEL P |4 aut | |
| 700 | 0 | |a HEGER KLAUS-DIETER |4 aut | |
| 700 | 0 | |a SALAZAR SANTIAGO VIVEROS |4 aut | |
| 700 | 0 | |a CIGNARELLA FRANCESCA |4 aut | |
| 700 | 0 | |a TASSI ILARIA |4 aut | |
| 700 | 0 | |a SCHWABE TINA |4 aut | |
| 700 | 0 | |a YEE ANGIE GRACE |4 aut | |
| 700 | 0 | |a ROSENTHAL ARNON |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 04. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:04 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72139691/publication/CA3145885A1?q=CA3145885 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 04 |c 02 | ||